Ginkgo Bioworks acquires cell therapy assets from Modulus Therapeutics, boosting CAR-T research and development.

Ginkgo Bioworks, a cell programming company, acquires cell therapy assets from Modulus Therapeutics, including CAR and switch receptor libraries. The acquisition bolsters Ginkgo's CAR-T research and development, enhancing safety and efficacy of cell therapies with improved control and targeting. Modulus Therapeutics specializes in designing next-generation cell therapies for autoimmune diseases.